急性冠脉综合征患者血浆IL-6、MMP水平及瑞舒伐他汀的干预作用

目的 探讨急性冠脉综合征（ACS）患者体内血浆白细胞介素-6（IL-6）及基质金属蛋白酶-9（MMP-9）的变化以及瑞舒伐他汀对二者的干预作用.方法 纳入2011年3月～2011年11月邯郸市第一医院行冠脉造影确诊ACS患者55例（ACS组）,同期纳入胸痛行冠脉造影但结果正常者30例（对照组）,采用酶联免疫吸附法（ELISA）检测所有受试者IL-6和MMP-9水平,比较两组差异;ACS组患者口服瑞舒伐他汀（10mg/d）4周后再次检测IL-6和MMP-9血浆水平,比较治疗前、后的差异.结果 与对照组相比,ACS组IL-6和MMP-9水平均较高分别为：（23.76±5.78）ng/ml vs.（17.56±5.34）ng/ml和（19.87±5.68）mg/L vs.（16.59±5.13）mg/L],差异有统计学意义（P＜0.01）,ACS组患者服用瑞舒伐他汀4周后血浆IL-6和MMP-9水平明显下降（P＜0.05）.结论 炎症反应可能参与ACS的发病过程,瑞舒伐他汀具有抑制炎症反应的作用.

Levels of plasma inflammatory mediators of acute coronary syndrome and intervention effect of rosuvastatin

Objective To investigate the level changes of plasm interleukin-6 （IL-6） and metalloproteinase-9 （ MMP-9 ） and intervention effect of rosuvastatin in patients with acute coronary syndrome （ ACS ） . Methods The patients with ACS diagnosed by coronary angiography （ CAG, n=55, ACS group ） and patients with chest pain and normal CAG outcomes （ n=30, control group ） were chosen from Mar. 2011 to Nov. 201 l. The levels of IL-6 and MMP-9 were detected by using enzyme-linked immunosorbent assay （ ELISA ） and compared between two groups. ACS group was orally given rosuvastatin （ 10 mg/d ） for 4 weeks, and then the levels of 1L-6 and MMP-9 were detected again and compared before and after treatment. Results Compared with control group, the levels of IL-6 and MMP-9 were higher in ACS group （ 23.76 ± 5.78 ） ng/ml vs. （ 17.56 ± 5.34 ） ng/ml and （ 19.87 ± 5.68 ） mg/L vs. （ 16.59 ± 5.13 ） mg/L, P〈0.01]. After taking rosuvastatin for 4 weeks, the levels of IL-6 and MMP-9 decreased significantly in ACS group （ P〈0.05 ） . Conclusion Inflammatory response may take part in the pathogenesis of ACS, and rosuvastatin has the effect of inhibiting inflammatory response.